What is Sim&cure?
Sim&cure is a specialized medical technology firm dedicated to improving patient outcomes in the treatment of brain aneurysms. The company distinguishes itself through a multifactorial approach that integrates advanced imaging diagnostics with tailored therapeutic solutions. Its flagship offering, SimSize, serves as a critical tool for surgeons, enabling higher precision in surgical planning and execution. By fostering strategic partnerships with imaging providers, Sim&cure effectively bridges the gap between diagnostic data and clinical intervention. The company's business model is centered on optimizing hospital workflows and reducing systemic costs, thereby providing a dual value proposition of clinical efficacy and economic efficiency for healthcare systems worldwide.
How much funding has Sim&cure raised?
Sim&cure has raised a total of $11.7M across 1 funding round:
Other Financing Round
$11.7M
Other Financing Round (2025): $11.7M with participation from SWEN Capital Partners, IRDI Capital Investissement, Elaia Partners, and Sofilaro
Key Investors in Sim&cure
SWEN Capital Partners
SWEN Capital Partners is a responsible investor specializing in private equity, infrastructure, and private debt, focused on creating sustainable value through Tech for Good and Climate Impact initiatives.
IRDI Capital Investissement
IRDI Capital Investissement is a major investment partner for innovation in SMEs and mid-sized enterprises, providing equity investment to foster sustainable and innovative growth in the South-West of France.
Elaia Partners
Elaia is a full stack investor focused on supporting ambitious entrepreneurs from inception to leadership, specializing in backing tech disruptors with a focus on performance and values.
What's next for Sim&cure?
Looking ahead, the infusion of capital will likely be directed toward scaling the deployment of SimSize and expanding the company's reach into new international markets. As Sim&cure transitions into a more mature phase of its lifecycle, the focus will shift toward deepening its integration within hospital networks and refining its suite of digital health tools. The strategic backing from its current investor base provides not only the necessary liquidity for growth but also access to a robust network of expertise in sustainable finance and regional innovation. Future efforts will likely prioritize the development of next-generation diagnostic algorithms and the expansion of its therapeutic portfolio, ensuring that the company remains at the forefront of neurovascular innovation while maintaining its commitment to patient-centric care.
See full Sim&cure company page
